SEC Filing Analysis: Revolution Medicines, Inc.

Executive Summary

• Trading Significance: Low
• Key Takeaway: Director Mark A. Goldsmith proposes a $1.32M sale of common stock derived from RSU grants under a pre-existing 10b5-1 plan.
• Market Impact: Negligible; transaction size is immaterial relative to the company's $19.69B market capitalization.

Company Information

Field	Value
Company	Revolution Medicines, Inc.
CIK	0001628171
Industry	Biological Products

Insider Information

Field	Value
Name	Mark A. Goldsmith
CIK	0001246842
Title/Position	Officer, Director
Relationship	Officer, Director

Transaction Details

Field	Value
Form Type	144 (Notice of Proposed Sale)
Transaction Date	2026/03/16 (Approximate)
Transaction Code	S (Proposed)
Security Type	Common Stock
Shares Involved	13,261
Price Per Share	~$99.59 (Implied)
Total Value	$1,320,662.99
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$1,320,662.99
% of Market Cap	0.0067%
Shares Transacted	13,261
% of Shares Outstanding	0.0069%
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With a market capitalization of $19.69 billion, a $1.32 million transaction is statistically insignificant (less than 0.01% of value).
• Dilution Impact: N/A (Secondary market sale).
• Transaction Significance: The transaction volume is extremely low relative to the float and total shares outstanding. It does not signal a shift in insider sentiment.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale is executed under a 10b5-1 plan adopted nearly three years ago (May 2023), indicating this is a scheduled liquidity event rather than a reaction to current market conditions.

Volume & Sentiment

• Expected Volume Impact: None. The share count is negligible compared to daily trading volumes for a large-cap biotech.
• Sentiment Indicator: Neutral. The sale is consistent with standard executive compensation liquidation (RSU vesting).

Additional Context

Transaction Notes

• 10b5-1 Plan: The filing notes a plan adoption date of 05/31/2023, confirming this trade was scheduled well in advance.
• Source of Shares: Shares were acquired via Restricted Stock Unit (RSU) grants vesting between 2022 and 2025.
• Recent Activity: The reporting person has sold approximately $4.8 million in stock over the past 3 months, consistent with a programmatic selling schedule.